Archives
-
Chloroquine Diphosphate: Flux, Readouts & HBV
2026-09-01
Chloroquine Diphosphate is more than an autophagy inhibitor: it is a strategic flux perturbant for cancer research and HBV-associated innate-immunity studies. This guide connects lysosomal readouts with the 2025 TBK1–HBsAg mechanism to improve assay design and interpretation.
-
Polybrene Workflows for Efficient Cell Engineering
2026-09-01
Polybrene supports more than routine lentiviral delivery: it can be optimized for retroviral transduction, lipid-mediated DNA transfection, and selected analytical assays. This practical guide combines concentration screening, exposure control, and assay-specific validation with a targeted-protein-degradation use case inspired by recent FBXO22 research.
-
Sulfamonomethoxine Toxicity Across Aquatic Trophic Levels
2026-08-31
Huang and colleagues evaluated sulfamonomethoxine toxicity across algae, cladocerans, and fish, combining short-term and chronic bioassays to compare sensitivity among aquatic organisms. The study identifies microalgae as particularly responsive test systems and provides a useful framework for interpreting antibiotic residues in aquaculture effluents, while also highlighting the limits of transferring laboratory concentrations directly to environmental risk.
-
LINC01278, mTOR, and Autophagy in Uveal Melanoma
2026-08-31
The reference study identifies LINC01278 as an autophagy-related long noncoding RNA that suppresses uveal melanoma progression through inhibition of mTOR signalling. Its combination of bioinformatics, pharmacological perturbation, pathway testing, and xenograft validation provides a useful framework for evaluating lncRNA-mediated control of tumour autophagy, while also highlighting the need to interpret MG-132 experiments with pharmacological caution.
-
EZ Cap™ Cas9 mRNA (m1Ψ) for Reliable Assays
2026-08-30
A scenario-driven guide to improving CRISPR-Cas9 genome editing workflows that intersect with viability, proliferation, and cytotoxicity assays. It explains how EZ Cap™ Cas9 mRNA (m1Ψ), SKU R1014, can support controlled, interpretable experiments through defined Cap1 capping, m1Ψ modification, poly(A) content, and practical handling specifications.
-
Morning Training Improves Endurance Adaptation in Mice
2026-08-29
Hesketh et al. show that endurance training during the early active phase produces faster and more efficient performance adaptation than training during the late active phase in female mice. The study links this effect to skeletal-muscle oxidative and contractile remodeling rather than differences in final glycogen content, while also highlighting important limits for translation to human exercise timing.
-
Annexin V-Cy5/DAPI Apoptosis Kit Workflow
2026-08-28
Build a rapid cell death workflow that separates viable, early apoptotic, and membrane-compromised populations in leukemia and cytotoxicity studies. The Annexin V-Cy5/DAPI Apoptosis Kit is especially useful for connecting treatment response with the P2RX1–CaMKII–PI3K/Akt apoptosis model described in Ph-positive acute lymphoblastic leukemia.
-
Annexin V-Cy5/DAPI Apoptosis Kit Guide
2026-08-28
A scenario-based guide to selecting, running, and interpreting the Annexin V-Cy5/DAPI Apoptosis Kit (SKU K2255) for apoptosis and necrosis studies. It connects phosphatidylserine detection with practical controls, flow cytometry and microscopy workflows, and mechanistic evidence from leukemia research.
-
Hypoxia-Pathway Induction Restricts Measles and Nipah
2026-08-27
A 2025 study shows that pharmacological inhibition of prolyl-hydroxylase domain enzymes activates the HIF-dependent hypoxia response and restricts measles virus in vitro and ex vivo. The same strategy also reduced Nipah virus infection in hamster cerebellum and lung cultures, supporting host-directed antiviral investigation while leaving clinical efficacy unresolved.
-
Toremifene Versus Tamoxifen in Advanced Breast Cancer
2026-08-27
This Cochrane review evaluated whether toremifene provides clinically meaningful advantages over tamoxifen for advanced breast cancer. Its synthesis found no clear difference across tumor response, progression, survival, or selected adverse-event outcomes, while emphasizing limitations in trial quality and evidence certainty.
-
Bicinchoninic Acid Assay Kit K4102
2026-08-26
The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit K4102 measures low-concentration total protein samples, including many detergent-containing biochemical samples and cell lysates. It is intended for scientific research workflows such as sample normalization and should not be used for diagnostic, clinical, or medical testing.
-
Partial BACE Inhibition and Synaptic Transmission
2026-08-26
Satir et al. examined whether reducing amyloid-β production through partial BACE inhibition necessarily disrupts neuronal communication. Using primary cortical neurons and optical electrophysiology, the study found that moderate inhibition lowered Aβ secretion without measurable synaptic-transmission loss, whereas stronger inhibition produced functional impairment.
-
Primary Antibody Dilution Buffer for PCNSL Assays
2026-08-25
Translate single-cell findings on SLC2A5-driven fructose metabolism into reproducible tissue, cell, and RNA-localization assays. This workflow uses a BSA- and Triton X-100-containing antibody dilution buffer to improve practical control of background, antibody penetration, and signal consistency without overstating clinical relevance.
-
Pepstatin A in Aspartic Protease Workflows
2026-08-25
Pepstatin A provides a practical route to dissect pepsin, renin, HIV protease, and cathepsin D activity across purified-enzyme and cell-based models. This guide combines target-aware dosing, orthogonal validation, and troubleshooting with a metabolite-binding workflow adapted from a 2025 TET2 protocol.
-
BCA Protein Quantification Kit: Practical Guide
2026-08-24
The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit, SKU K4102, supports sensitive total-protein measurement for dilute samples and many detergent-containing lysates. It is intended for scientific research workflows such as protein quantification for cell lysates and biochemical sample normalization, not diagnostic, clinical, or medical testing.